Nabota: Daewoong's botulinum toxin, studies and natural results

You may have been offered Nabota instead of a more familiar botulinum toxin and be wondering whether your face will still look natural and whether this particular brand is trustworthy. Nabota is a brand of botulinum toxin type A made by the South Korean company Daewoong. It is a medicine used to reduce selected muscle activity temporarily, not a volume-adding filler. A related Daewoong product is marketed in the United States as Jeuveau (prabotulinumtoxinA-xvfs). US approval of Jeuveau does not mean that every pack labelled Nabota is automatically registered or authorised in Armenia.

What was studied, and what can this medicine change?

The strongest evidence for prabotulinumtoxinA concerns the vertical lines between the eyebrows when you frown. The US Jeuveau label has a narrow indication: temporarily improving the appearance of moderate to severe glabellar lines in adults. That American indication cannot simply be extended to the forehead or crow's feet. For Nabota sold under its own brand name, check the approved indications in the exact country's product information.

Botulinum toxin inhibits release of acetylcholine, the chemical signal that tells a muscle to contract. The targeted muscle contracts less strongly for a time, so a crease that deepens with expression can become softer. It cannot replace lost volume, remove pigmentation or lift sagging skin. A line already present at rest may soften only partly. If your aim is a different lip or face shape, you are considering another kind of treatment, not this toxin brand.

Looking natural is not guaranteed by the phrase “it won't freeze your face”. It depends on examining your facial movement, choosing the sites and dose, and respecting your preferences. One person wants to retain a slight frown; another wants the crease reduced as far as possible. These goals involve different trade-offs. Even careful treatment cannot promise perfectly symmetrical movement: the two sides of a face are not identical to start with.

Nabota, Jeuveau and Nuceiva: why the name on the pack matters

One manufacturer's products can carry different names and regulatory documentation in different markets. Jeuveau is the US-licensed name for prabotulinumtoxinA-xvfs; Nabota is used in other markets; Nuceiva is a name encountered in Europe. This is a reason to check origin, not to treat the names as interchangeable for purchasing, storage or prescribing. The status of the actual pack must be supported by applicable local official documentation.

In the European Union, Nuceiva has its own product information: its indication concerns moderate or severe glabellar lines with a substantial psychological impact in adults under 65, and administration is by an experienced doctor. The EU information lists myasthenia gravis and Eaton–Lambert syndrome as contraindications, whereas the US Jeuveau label separately warns of increased risk in people with neuromuscular disorders. You should not have to reconcile these rules yourself: the clinician must check the exact local prescribing information. EU authorisation does not establish Nabota's registration in Armenia.

What the offer says	What you can conclude	What it does not prove
“Nabota, made in Korea”	A brand and country of manufacture have been stated	That the vial is authentic, registered in your country or legally authorised for the proposed treatment area
“Jeuveau is FDA-approved in the US”	A particular prabotulinumtoxinA product has US marketing authorisation and its own approved label	That every version of Nabota can automatically be used in Armenia or for every wrinkle
“Stronger than Botox”	A marketing comparison that needs a clearly defined endpoint and dosage	Universal superiority for every face or area; dose units of different toxins cannot simply be converted
“Same formula, so we do not need to show the pack”	Nothing that can be verified	Authenticity, proper storage or access to reliable information about the actual medicine

Ask for the active ingredient, trade name, manufacturer, batch number, expiry date, storage conditions, supply source and relevant package information. It is useful for the lot number to be recorded in your medical notes. A social-media photograph cannot establish local availability: an advertised product is not necessarily legally distributed or authorised for use by the particular facility.

What do clinical studies really show — and not show?

A randomised double-blind phase III study involving 540 adults compared prabotulinumtoxinA, onabotulinumtoxinA and placebo for glabellar lines. On day 30, the proportions rated by investigators as having no or mild lines at maximum frown were 87.2%, 82.8% and 4.2%, respectively. PrabotulinumtoxinA met the prespecified statistical standard for non-inferiority in that specific comparison. This does not mean it is stronger, faster or safer for every individual.

Two additional controlled phase III trials found improvement in pronounced glabellar lines compared with placebo. Reported response rates depend on the definition of response, timing and participant selection. A day-30 endpoint cannot promise an equivalent result the day after treatment, and evidence about the glabellar area does not establish effectiveness everywhere on the face. Your anatomy, earlier injections and medication history also matter.

You may see promotional statements about Nabota's purification process or high purity. These are manufacturing or technical attributes, not independent proof of fewer allergic reactions, no neutralising antibodies or a longer-lasting effect. Such comparisons require appropriate clinical outcomes, comparable doses and long-term follow-up. A single number on an advertisement is not a sound basis for choosing a medicine.

What happens during injection, and when do you see a change?

Before treatment, the clinician asks you to frown, raise your eyebrows and relax, then examines lid position, crease depth and symmetry. After cleansing your skin, they make small intramuscular injections at selected points. People often describe brief pinpricks or pressure; discomfort varies. If you feel anxious, discuss ways to stay comfortable and the option of a break rather than silently enduring it.

Immediately afterwards you may notice injection marks, redness, slight swelling or a bruise. These are not the toxin's final effect. Muscle relaxation develops gradually at different rates. Do not judge symmetry or request an immediate “top-up” on the injection day; agree on an appropriate review date with your clinician. Duration is usually discussed in terms of months, but an exact period is not guaranteed and repeat treatment depends on the specific instructions and medical assessment.

The US Jeuveau label states that repeat treatment should be no more frequent than every three months. This rule applies to that US product and indication, not automatically to every package in every market. Trying to prolong an effect by increasing doses or frequency on your own is unsafe. When considering a different toxin brand, the clinician must re-check activity units: they are product-specific, not a common unit of milligrams.

You have a big event: when should treatment be planned?

For a meeting, wedding or photo session, think in two timelines. Social visibility includes possible bruises, puncture marks, emerging asymmetry and how gradually the effect appears, even if you can work as usual. Medical follow-up concerns adverse effects and the right time to assess the outcome. Nobody can guarantee that your face will match an advertising photograph by a particular morning.

Most people can discuss resuming ordinary daily activities without prolonged rehabilitation, but the injector should give individual advice about exercise, massage, other cosmetic treatments and skin care for your injection sites. Do not assume advice from a video featuring another product applies to Nabota. If even temporary visible marks or unfamiliar eyebrow movement would be unacceptable, choose a date with breathing room or avoid injections before the event.

What is a possible reaction, and when should you seek help?

Possible effects include tenderness at injection sites, headache, minor bruising and unintended weakening of neighbouring muscles, such as a drooping eyelid or eyebrow. Headache and eyelid ptosis were among events seen in US Jeuveau trials; appearing in a label does not mean they will happen to you. Tell your treating clinician about noticeable asymmetry or eye discomfort; do not attempt to reverse or adjust the outcome yourself.

Seek urgent medical assessment for pronounced unusual generalised weakness, sudden double vision or another new visual disturbance, changes in speech, or difficulty swallowing or breathing after a botulinum toxin injection. The official US label warns that toxin effects may spread beyond the injection site; related symptoms may appear hours to weeks later. Do not wait for a routine review; call emergency services for breathing, swallowing or speech difficulties.

An allergic reaction with breathlessness, wheezing, substantial swelling or fainting also needs emergency treatment. Plan beforehand where you can go outside office hours. Report severe dry eyes, light sensitivity and visual changes as well: weakening of muscles around the eyes may warrant assessment by an eye specialist.

Who may not be a good candidate?

Under the US Jeuveau label, known hypersensitivity to botulinum toxins or formulation ingredients and infection at the injection site are contraindications. Neuromuscular diseases such as myasthenia gravis, existing swallowing or respiratory difficulties, marked muscle weakness and eyelid drooping require particular caution. A clinical assessment should also cover facial surgery, reactions to previous injections, dry eyes, bleeding problems and serious associated conditions. Other markets may list additional explicit contraindications, as noted for Nuceiva above.

Tell the clinician about all prescription and non-prescription medicines, especially aminoglycoside antibiotics, muscle relaxants, other drugs affecting neuromuscular transmission and any other botulinum toxin treatment. Do not stop prescribed treatment yourself. Reliable evidence for elective aesthetic use during pregnancy or breastfeeding is insufficient; the cautious option is to postpone and discuss your circumstances with your clinician.

Expectations are part of suitability. If you want a deep crease present at rest to disappear completely or your cheeks to gain volume, botulinum toxin alone is not the answer. Choosing not to have an optional procedure is not a failure. Skin care, a discussion of what causes the concern or simply retaining your normal facial movement may suit you better.

How can you fairly compare Nabota with alternatives?

The closest alternatives are other type A botulinum toxin products, each with its own clinical evidence and prescribing information. Their mechanisms are broadly similar, but formulations, approvals, storage rules and activity assays differ. A clinician should use verified product documents rather than copy units from another brand's protocol. Our separate guide to Letybo discusses another specific toxin without merging its indications with those for Nabota.

When looking at before-and-after photos, check facial expression, whether the degree of frowning matches, lighting, angle and time since injection. We consider images in more detail in our guide to Nabota before and after. Images of the face both relaxed and moving are more useful than a single perfectly smooth frown line.

Before consenting, ask to see the chosen product's packaging and valid local instructions. Ask why that area is recommended, what will not change, what adverse effects to watch for, when results will be reviewed and what happens if you have a complication. Request a full quote for your specific care rather than assuming prices are uniform across cities. “Everyone does it; it is completely safe” is not an adequate answer.

You need not choose Nabota just because it was suggested or described as “newer”. A natural result depends on your own face, a qualified practitioner, a verified product and agreement on the trade-offs. Deciding to have no injections now is equally valid.

Additional questions

If a different toxin failed before, should I switch straight to Nabota?

First review the intended condition, timing of assessment, actual product, dose, technique and past injections. A lack of effect does not prove immune resistance or guarantee that another brand will work.

Can Nabota units and those of another brand be combined in one treatment plan?

There is no universal unit conversion. The clinician must follow the exact product information, consider cumulative exposure and document every product administered.

Can I judge safety from a tamper seal or QR code?

A seal or code may help trace origin, but does not alone establish lawful supply, correct storage, registration or practitioner competence. Documentation and a medical assessment are both needed.